Deborah Hursh, PhD (she/her/hers)

CBER/FDA

Deborah Hursh is a senior investigator in OTAT at CBER, FDA. She received a Ph.D. from Indiana University and did postdoctoral work at Harvard University. Dr. Hursh evaluates products derived from stem cells and participates in policy development in the areas of stem cells, assisted reproduction and xenotransplantation. She chaired the organizing committee for a CBER advisory meeting on oocyte and embryo modification for the prevention of transmission of mitochondrial disease and was the CMC subject matter expert for an OTAT advisory meeting on xenotransplantation. She is also the Principal Investigator of a research lab studying cell therapy products.

Presentation(s):

• BEST PRACTICES FOR THE TRANSLATION OF PLURIPOTENT STEM CELL-DERIVED THERAPIES

  Thursday, June 12, 2025
  8:30 AM – 10:00 AM HK Time